Heike Reinhardt

Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literature.

Journal: Annals of hematology

Published: December 25, 2024

Optimizing individualized therapy decision-making in multiple myeloma (MM): integration and impact of the Revised Myeloma Comorbidity Index in the MM-tumor board.

Journal: Annals of hematology

Published: May 16, 2024

Comorbidity indices for prognostic evaluation in multiple myeloma: a comprehensive evaluation of the Revised Myeloma Comorbidity Index and other comorbidity indices with pro- and retrospective applications.

Journal: Haematologica

Published: August 23, 2023

An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence.

Journal: Haematologica

Published: May 30, 2022

Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors.

Journal: Cancers

Published: July 21, 2021

Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort.

Journal: Cancer

Published: January 28, 2021

Ruxolitinib.

Journal: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer

Published: August 03, 2018

Pomalidomide.

Journal: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer

Published: August 03, 2018

Avoiding chemotherapy prescribing errors: Analysis and innovative strategies.

Journal: Cancer

Published: July 25, 2018

Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions.

Journal: Haematologica

Published: May 02, 2018

Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials^.

Journal: Leukemia & lymphoma

Published: March 24, 2018

GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study.

Journal: Clinical and experimental nephrology

Published: September 12, 2017

Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literature.

Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literature.

Optimizing individualized therapy decision-making in multiple myeloma (MM): integration and impact of the Revised Myeloma Comorbidity Index in the MM-tumor board.

Optimizing individualized therapy decision-making in multiple myeloma (MM): integration and impact of the Revised Myeloma Comorbidity Index in the MM-tumor board.

Comorbidity indices for prognostic evaluation in multiple myeloma: a comprehensive evaluation of the Revised Myeloma Comorbidity Index and other comorbidity indices with pro- and retrospective applications.

Comorbidity indices for prognostic evaluation in multiple myeloma: a comprehensive evaluation of the Revised Myeloma Comorbidity Index and other comorbidity indices with pro- and retrospective applications.

An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence.

An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherence.

Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors.

Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors.

Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort.

Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort.

Ruxolitinib.

Ruxolitinib.

Pomalidomide.

Pomalidomide.

Avoiding chemotherapy prescribing errors: Analysis and innovative strategies.

Avoiding chemotherapy prescribing errors: Analysis and innovative strategies.

Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions.

Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions.

Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials.

Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials.

GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study.

GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study.

Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials^.

Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials^.